Patient Education
Share your love
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ | Ophthalmology Times
(Image Credit: AdobeStock/Rawf8) LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZ for the treatment of presbyopia in adults…
Phase 1 trial confirms safety and tolerability of Huons’ dry eye therapy | Ophthalmology Times
(Image Credit: AdobeStock) Huons Co, a pharmaceutical subsidiary of Huons Group, received phase 1 Clinical Study Results (CSR) for HUC1-394, an eye drop for the treatment of dry eye disease (DED). HUC1-394 is a peptide-based eye drop for dry eyes,…
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/doucefleur) Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease type 1 (STGD1). According to the company, this marks the first successful pivotal trial in patients with the…
Kiora Pharmaceuticals receives patent for additional and novel formulations of KIO-100 compounds | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of the KIO-100 family of compounds from Kiora Pharmaceuticals. In July 2025, the company announced it had…
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week | Ophthalmology Times
(Image Credit: AdobeStock/Marina April) Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the public and raise awareness. The Cleveland Clinic states that more than 8 million people in the…
Collarettes common but largely stable in moderate-to-severe dry eye patients | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) In utilizing the Dry Eye Assessment and Management (DREAM) study data, a team of researchers found that lid margin collarettes were common in patients with moderate-to-severe dry eye disease (DED), but a majority of those patients’…
Q&A: As DMEI turns 50, R. Michael Siatkowski, MD, MBA, looks to the future | Ophthalmology Times
R. Michael Siatkowski, MD, MBA, reflects on 50 years of innovation, research, and patient care at the Dean McGee Eye Institute and shares his vision for the future of ophthalmology. (Courtesy of Dean McGee Eye Institute) As Dean McGee Eye…
AAO 2025 Takeaways: A new biomechanical paradigm for presbyopia | Ophthalmology Times
(Image Credit: AdobeStock/natali_mis) Editor’s Note: This content was generated with the assistance of AI. While much of AAO 2025 centered on therapeutics and imaging, AnnMarie Hipsley, PhD, delivered one of the meeting’s most paradigm-shifting talks by re-framing presbyopia as a…
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined | Ophthalmology Times
(Image Credit: AdobeStock/Pixel-Shot) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 delivered major insights into anterior segment innovation, spanning corneal cross-linking care, refractive surgery evolution, and energy-based aesthetic technology. Presentations from Reena Gupta, MD; Arjan…
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…